Shares in Midatech Pharma PLC rose Thursday after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.
Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body which release the drug over predictable, sustained periods from one week to several months.
The U.K. biotechnology company, which is listed on London’s AIM market and on the Nasdaq, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.
Shares at 0725 GMT were up 5.0 pence, or 18.2%, at 32.5 pence.